In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Transderm, Inc.

Latest From Transderm, Inc.

2012 Scrip 100: Drug delivery innovations bring compliance and cost savings

Patient noncompliance places a huge cost on healthcare budgets on a global level. Peter Thornton looks at new drug delivery options that could solve this costly problem, as healthcare providers come under pressure to control ever escalating costs.

Metabolic Disorders Cardiovascular

Deals Shaping the Medical Industry (06/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Executive Briefing - Oligonucleotide therapeutics: the next big thing

1953 was an extraordinary year for biology, an annus mirabilis, or wonder year, which offered scientific insights to rival those made by Einstein almost half a century earlier.

Metabolic Disorders Cardiovascular

TransDerm Inc.

TransDerm is a California start-up developing short interfering RNAs to treat a rare genetic disease called pachyonychia congenita.

BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal